Key Takeaways
- Novo Nordisk has secured licensing rights to HRS-1596, an experimental obesity pill developed by China’s Jiangsu Hengrui Pharmaceuticals, for up to $2.6 billion.
- Hengrui will receive $300 million immediately, with an additional $2.3 billion potentially payable through development, regulatory, and commercial milestones.
- HRS-1596 is a dual GLP-1/GIP receptor agonist designed for weekly administration in pill form.
- Shares of Novo have plummeted over 70% from peak levels amid intensifying competition from Eli Lilly in the obesity drug sector.
- Following the announcement, Hengrui’s Hong Kong-traded shares climbed approximately 2%.
After watching its stock collapse more than 70% from all-time highs while Eli Lilly erodes its dominance in the obesity treatment space, Novo Nordisk announced a significant strategic move on Tuesday.
The Copenhagen-based pharmaceutical giant struck a deal worth up to $2.6 billion to obtain rights for an investigational weight-loss pill from Jiangsu Hengrui Pharmaceuticals, a Chinese biotech firm. This represents Novo’s second GLP-1 licensing arrangement with a Chinese company in 2025.
Under the terms, Novo acquires worldwide commercialization rights to HRS-1596, excluding mainland China, Hong Kong, Macao, and Taiwan. Hengrui retains exclusive rights in those Greater China territories.
HRS-1596 functions as a dual GLP-1/GIP receptor agonist and remains in early-stage clinical development. Chinese regulatory authorities have greenlit Phase 1 studies examining its potential for obesity management and type 2 diabetes treatment.
Financial Structure of the Transaction
The Chinese pharmaceutical company will collect $300 million upfront. The remaining $2.3 billion portion consists of contingent payments tied to development progress, regulatory approvals, and commercial performance, alongside royalty payments on net sales.
Novo indicated the oral medication is being developed for once-weekly administration. This represents a significant advancement over existing daily pill formulations, including those in Novo’s current portfolio like Wegovy.
Chief Executive Officer Mike Doustdar stated earlier in April that oral formulations will become increasingly central to obesity therapeutics. Tuesday’s licensing agreement aligns directly with this strategic vision.
A company representative informed Reuters that Novo intends to initiate international clinical trials for HRS-1596, though specific timelines remain undisclosed.
The Battle With Lilly and China’s Rising Role
Novo finds itself in fierce competition with Eli Lilly, whose oral medication Foundayo directly challenges Wegovy in the marketplace. This competitive pressure has significantly impacted Novo’s share price in recent months.
The Chinese pharmaceutical industry has emerged as a powerhouse in obesity drug development. According to analytics firm Pharmcube, nearly 250 GLP-1 programs originating from Chinese companies are currently advancing through various development stages.
Multiple multinational pharmaceutical corporations have pursued similar strategies. Companies including AstraZeneca, Merck, and Pfizer have all executed licensing agreements for GLP-1 candidates discovered by Chinese biotechnology firms.
Novo previously established a partnership with United Laboratories International, another Chinese enterprise, for UBT251. Clinical data showed patients achieved weight reduction of up to 19.7% over a 24-week treatment period.
Industry analysts project the global obesity therapeutics market will reach approximately $100 billion in annual revenue within the coming decade. This enormous commercial opportunity explains the surge in licensing transactions across the sector.
Hengrui’s Hong Kong-listed shares gained roughly 2% following the announcement. This positive movement contrasted with the broader Hang Seng Index, which declined about 1% during the same trading session.
The transaction remains subject to U.S. antitrust clearance and standard regulatory approvals. Both Novo and Hengrui anticipate finalizing the agreement during the fourth quarter of 2026.
Eli Lilly declined to provide comment when asked whether the company has pursued comparable licensing arrangements with Chinese pharmaceutical developers.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
